Does Hydroxychloroquine Improve Glycemic Status and Lipid Profile in Rheumatoid Patients with Diabetes Mellitus – An Observational Study
Article Sidebar
-
Rheumatoid Arthritis (RA), Diabetes Mellitus (DM), Hydroxychloroquine (HCQ), Lipid Profile
Abstract
Rheumatoid arthritis is an autoimmune disease, causing chronic inflammation of small joints in hands and feet. The chronic inflammation and corticosteroid use in rheumatoid patients predispose them to insulin resistance and diabetes. Hydroxychloroquine, a proven drug in rheumatoid arthritis, seems to be beneficial in diabetes and also reduces the risk of cardiovascular events. This study was done to find out the role of hydroxychloroquine on the glycemic status and lipid profile in Rheumatoid patients having treatment with Diabetes mellitus. 50 patients with both RA and DM in the middle age group were categorized into HCQ and Non-HCQ group. Both the groups were followed up for 6 months. Their glycemic status and lipid profile were compared by measuring FBS, PPBS, HbA1C, triglycerides, total cholesterol, VLDL, LDL and HDL. Statistical analysis was done by student t test. The mean FBS, PPBS, HbA1C values in HCQ Group patients decreased significantly from 155.16, 200.12 and 8.26 to 135.80, 174.60 and 7.49 respectively in the follow-up period. In the Non-HCQ group, there was no significant change in mean FBS and PPBS after 6 months. Mean HbA1C increased from 8.13 to 8.33 in Non-HCQ group. Triglycerides, total cholesterol, VLDL and LDL also were found to be reduced in patients who had taken HCQ. In Rheumatoid patients with diabetes, use of HCQ improves their glycemic status and reduces the lipid abnormalities.
Full text article
References
Akhavan, P. S., et al. 2013. The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology, 40(6):831– 841.
Bili, A., et al. 2011. Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients. Journal of Clinical Rheumatology, 17(3):115–120.
Booth, G. L., et al. 2006. The relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. The Lancet, 368(9529):68967–68975.
Emami, J., et al. 1998. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sciences, 64(5):325–335.
Emami, J., et al. 1999. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Canadian Journal of Physiology and Pharmacology, 77(2):118–123.
Gerstein, H. C., et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet, 368(9541):1096–1105.
Jagnani, V. K., et al. 2017. Effect of Hydroxychloroquine on Type 2 Diabetes Mellitus Unresponsive to More Than Two Oral Antidiabetic Agents. Journal of Diabetes & Metabolism, 8(10):1–6.
Jin, J., et al. 2017. Increased risk of diabetes in inflammatory orthopedics diseases. AME Medical Journal, 2:71.
Mercer, E., et al. 2012. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Research & Therapy, 14(3):R135.
Mokdad, A. H., et al. 2001. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors. Journal of the American Medical Association, 289(1):76–79.
Morris, S. J., et al. 2011. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care & Research, 63(4):530–534.
O’Dell, J. R., et al. 1996. Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications. New England Journal of Medicine, 334(20):1287–1291.
Pareek, A., et al. 2014. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Current Medical Research and Opinion, 30(7):1257–1266.
Petri, M. 1996. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus, 5(1_suppl):16–22.
Petri, M., Yoo, S. S. 1994. Predictors of glucose intolerance in systemic lupus erythematosus. Arthritis Rheum, 37(9):S323.
Powrie, J. K. 1991. Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. American Journal of Physiology Endocrinology and Metabolism, 260(6):E897– E904.
Quatraro, A. 1990. Hydroxychloroquine in Decompensated, Treatment-Refractory Noninsulin Dependent Diabetes Mellitus. Annals of Internal Medicine, 112(9):678.
Ramser, B., et al. 2009. Hydroxychloroquine Modulates Metabolic Activity and Proliferation and Induces Autophagic Cell Death of Human Dermal Fibroblasts. Journal of Investigative Dermatology, 129(10):2419–2426.
Rekedal, L. R., et al. 2010. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis & Rheumatism, 62(12):3569–3573.
Restrepo, J. F., et al. 2017. Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. JCR: Journal of Clinical Rheumatology, 23(3):144–148.
Shojania, K., et al. 1999. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. The Journal of Rheumatology, 26(1):195–196.
Silman, A. J., Pearson, J. E. 2002. Epidemiology and genetics of rheumatoid arthritis. Arthritis research & therapy, 4(S3):S265.
Tam, L. S., et al. 2000. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. The Journal of rheumatology, 27(9):2142–2145.
Wasko, M. C. M., et al. 2007. Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis. Journal of the American Medical Association, 298(2):187–193.
Weber, S. M., Levitz, S. M. 2000. Chloroquine Interferes with Lipopolysaccharide-Induced TNF- α Gene Expression by a Nonlysosomotropic Mechanism. The Journal of Immunology, 165(3):1534– 1540.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.